3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
38
Neoplasm Metastasis
14
Liver Neoplasms
11
Colorectal Neoplasms
11
Cholangiocarcinoma
9
Pancreatic Neoplasms
8
Lung Neoplasms
8
Colonic Neoplasms
7
Breast Neoplasms
7
Thyroid Nodule
6
Recurrence
6
Carcinoma, Renal Cell
6
Carcinoma, Non-Small-Cell Lung
6
Thyroid Neoplasms
5
Rectal Neoplasms
4
Neoplasms
4
Esophageal Neoplasms
4
Prostatic Neoplasms
3
Pain
3
Kidney Neoplasms
3
Barrett Esophagus
3
Agnosia
3
Thyroid Diseases
2
Thyroid Cancer, Papillary
2
Leiomyoma
2
Hyperaldosteronism
2
Gallbladder Neoplasms
2
Cancer Pain
2
Bile Duct Neoplasms
2
Adrenocortical Adenoma
2
Interventions
Cisplatin
3
anlotinib
2
Sunitinib
2
Radiotherapy, Intensity-Modulated
2
Gemcitabine
2
Carboplatin
2
olaparib
1
niraparib
1
ixabepilone
1
Taxes
1
Sorafenib
1
Radiofrequency Ablation
1
Paclitaxel
1
Nimorazole
1
Irinotecan
1
Filgrastim
1
Endoscopic Mucosal Resection
1
Cobicistat
1
Chemoradiotherapy
1
Capecitabine
1
CP protocol
1
Bevacizumab
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasms, Glandular and Epithelial
×
Radiofrequency Ablation
×
Clear all
NCT02192671
2022-01-18
HR-HCC/PHT
Guangxi Medical University
Phase 3
Unknown
120 enrolled